Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Stopped The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplasm of Colon
- Malignant Neoplasm of Lung
- Malignant Neoplastic Disease
Interventions
- DRUG: MRTX849
- DRUG: BI 1701963
Sponsor
Mirati Therapeutics Inc.
Collaborators